Diabetes News You Can Use

GLP-1 drug may mitigate Parkinson’s progression

A small study published in The New England Journal of Medicine suggests that a GLP-1 receptor agonist similar to the diabetes medication Ozempic and obesity drug Wegovy may lead to modest slowing of Parkinson’s disease symptoms. Parkinson’s expert Michael Okun called the findings “a really encouraging step forward,” and Hyun Joo Cho of the National Institute of Neurological Disorders and Stroke said the study is important but further research is needed.

 Full Story: The New York Times 

Semaglutide tied to heart failure benefits for patients with T2D

Patients with type 2 diabetes and obesity-related heart failure with preserved ejection fraction received weight loss and heart failure benefits with semaglutide, according to a study in the New England Journal of Medicine, mirroring the results of a study in The Lancet. “Consistency between the findings of the two trials provides greater reassurance that semaglutide is an efficacious treatment option with a favorable safety profile in a broad population” with HFpEF related to obesity, the researchers said.

Full Story: MedPage Today (free registration)

Study of T1D in adults provides new insights

A study published in the journal The Lancet Diabetes and Endocrinology, based on data from over 2.8 million people, examined the development of type 1 diabetes in adults. The study found that heritability is lower for T1D in adults than children, indicating environmental factors may play a more significant role in adults, lead researcher Yuxia Wei said.

 Full Story: Medical Xpress (4/1)  

Tirzepatide may lead to better glucose control

A study published in the journal Diabetes Care found that treatment with tirzepatide significantly improved A1C and postprandial glucose levels for patients with type 2 diabetes, compared with basal insulins degludec and glargine. The use of tirzepatide also was associated with a decrease in body weight.

 Full Story: Medscape (4/3)  

SGLT2 inhibitors linked to greater MASLD regression

A nationwide cohort study in JAMA Internal Medicine of 80,178 patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes treated with oral antidiabetic medication found that sodium-glucose cotransporter 2 inhibitors were associated with a higher probability of MASLD regression and lower adverse liver-related outcomes compared with other antidiabetic drugs. “SGLT2 inhibitors were distinguished by their association with fatty liver improvement, surpassing other [oral antidiabetic drugs] known for their potential benefits in MASLD,” said Dr. Won Kim, a study author.

Full Story: Healio (free registration) (3/13)  

Metabolic syndrome may increase cancer risk by 30%

People with metabolic syndrome had a 30% higher chance of developing cancer over the course of a decade after diagnosis, according to a study published in the journal Cancer. The researchers also studied inflammation by tracking C-reactive protein, concluding that elevated levels of the protein along with metabolic syndrome “significantly associated with subsequent breast, endometrial, colorectal and liver cancers.”

 Full Story: National Public Radio (3/11)  

Group recommends glucose challenge to assess T2D risk

An International Diabetes Federation position statement in Diabetes Research and Clinical Practice written by a 22-member international expert panel recommends a one-hour 75-gram oral glucose tolerance test to identify those at risk for type 2 diabetes. “There are many, many people who may appear ‘normal’ if you use A1c or fasting glucose, but if you do a glucose tolerance test, they may have an abnormality after a glucose load,” lead author Dr. Michael Bergman said.

 Full Story: Medscape (3/11)  

Marijuana users more likely to have heart attack, stroke

A study published in the Journal of the American Heart Association found that users who eat, smoke or vape marijuana have increased odds of experiencing stroke and heart attack, regardless if they do not vape or smoke tobacco or if they have no existing heart conditions. Researchers found that the risk rose as the number of days of marijuana use increased.

 Full Story: CNN (2/28)  

Large study identifies genetic risks tied to T2D

The most extensive genome-wide association study of type 2 diabetes has identified eight non-overlapping clusters of genetic variants tied to disease characteristics and cardiovascular risk factors. The findings in the journal Nature “will empower us to improve the lives of people with diabetes with new treatments, new ways of care, new ways of [treating] it in the future, through prediction of individual susceptibility or ability to distinguish potential subtypes of diabetes,” said Inga Prokopenko, a professor at the University of Surrey who was not involved in the study.

 Full Story: Medical News Today (2/28)  

Study: Diet rich in plant-based foods may reduce T2D risk

A study involving 11,965 middle-aged adults showed that eating a diet rich in plant-based foods was more likely to reduce the risk of Type 2 diabetes than reducing intake of non-red meat animal products, according to the findings published in Diabetes Care. Researchers wrote that “emphasizing plant foods may be an effective dietary strategy to delay or prevent the onset of diabetes.”

 Full Story: Medscape (free registration) (2/19)